Tech

Bio-Techne Stock (NASDAQ:TECH), Trade Ideas

Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

News

Health Care

Initiation

Analyst Ratings

General

TECH

William Blair has initiated coverage on coverage of Bio-Techne Corp (NASDAQ: TECH) with a

Life Science Firm Bio-Techne&#39;s Success Formula: Astute Acquisitions Offering Transformation

Large Cap

Bio-Techne Corporation (NASDAQ: TECH) has agreed to acquire Lunaphore Inc with 

Bio-Techne&#39;s Acquisition of Lunaphore Expands Its Spatial Biology Offerings

Analyst Color

Downgrades

Movers

ABCM

MKGAF

MKKGY

RVTY

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22, 

Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation

Bio-Techne Corp

TECHNOLOGY MTLS AUSTRALIA by TECHNOLOGY METALS AUSTRALIA LTD

TECHNOPROBE SPA U/ADR by TECHNOPROBE SPA

Tech Central Inc

TechStackery, Inc

TechTarget Inc

Techcom Inc

Techmatrix Corp

TechniScan Inc

TECHNICAL COMMUNICATIONS by Technical Communications Corp.

Technical Communications Corp

TECHNIP ENERGIES S/ADR by Technip Energies NV

Technip Energies NV

TECHNIP ENERGIES NV by Technip Energies NV

TechnipFMC PLC

TECHNO HORIZON CO LTD by Techno Horizon Co Ltd.

Techno Horizon Co Ltd

TECHNOPRO HLDGS INC ORD by Technopro Holdings Inc.

TechnoPro Holdings Inc

TECHNOPRO HLDGS SP/ADR by Technopro Holdings Inc.

Technogym SpA

Technology & Telecommunication Acquisition Corporation - Warrant

Technology & Telecommunication Acquisition Corp

Technology & Telecommunication Acquisition Corporation - Class A Ordinary Shares

Technology & Telecommunication Acquisition Corporation - Unit

TECHNOLOGY GENERAL CORP by Technology General Corp.

Technology General Corp

TECHNOLOGY ONE LTD by Technology One, Ltd.

Technology One Ltd

TECHNOLOGY SLTNS CO by Technology Solutions Company

Technology Solutions Co

TECHNOVATIVE GRP INC by Technovative Group, Inc.

Technovative Group Inc

Techpoint Inc

Techprecision Corp

TECHTRONIC INDUS CO ORD by Techtronic Industries Ltd.

Techtronic Industries Co Ltd

TECHTRONIC INDUS LTD ADR by Techtronic Industries Ltd.

Techwing Inc

TechyBird Acquisition Corp

<p>The BMP kit runs on Bio-Techne&#39;s Ella&trade;, a benchtop automated immunoassay platform leveraging Bio-Techne&#39;s R&amp;D Systems branded reagents to deliver accurate, reliable, and highly reproducible data in less than 90 minutes. Ella&#39;s microfluidic-based cartridges with separate channels enable precision multiplexing in a hands-free system, making it ideal for diagnostic clinical use. Novomol-Dx relied on a proprietary algorithm to develop the normative data, disease-associated data, and AI-based predictive algorithms for ocular surface and retinal conditions. The complete solution is branded as BioM-Pathfinder. The novel applications for the BMP kit are in Dry Eye Disease, Diabetic Retinopathy and patient stratification or monitoring associated with ocular surgeries and treatments.&nbsp;</p>


Contracts

Bio-Techne And Novomol-Dx Have Announced The Development Of Bio-marker Pathfinder, An Ocular Biomarker Kit, As A Point-Of-Care Application

<p>In the preceding three months, 4 analysts have released ratings for Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.25, along with a high estimate of $87.00 and a low estimate of $65.00. Experiencing a 11.54% decline, the current average is now lower than the previous average price target of $87.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456109_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Bio-Techne is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Techne. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Bio-Techne's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Techne's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TECH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bio-Techne analyst ratings.</strong></a></p>
<h2>About Bio-Techne</h2>
<p>Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.</p>
<h3>Bio-Techne's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Bio-Techne showcased positive performance, achieving a revenue growth rate of <strong>0.37%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Bio-Techne's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.07%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bio-Techne's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.39%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.0%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.28</strong>, Bio-Techne adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 4 Analyst Ratings For Bio-Techne

<p>Deutsche Bank  analyst Justin Bowers   maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $85 to $82.</p>


Price Target

Deutsche Bank Maintains Buy on Bio-Techne, Lowers Price Target to $82

<p>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne&#39;s Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope&trade;&nbsp;ISH technology. Over&nbsp;50%&nbsp;of these publications were released in the past 3 years, as increasing global customer awareness and expanded market adoption solidify ACD&#39;s leadership in spatial biology applications.</p>


Bio-Techne Surpasses 10K Peer-Reviewed Publications Citing Rnascope Technology

<p>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) is pleased to announce that <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4126836-1&amp;h=4263876927&amp;u=https%3A%2F%2Flunaphore.com%2F&amp;a=Lunaphore">Lunaphore</a>, part of Bio-Techne's Spatial Biology Division, is partnering with&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4126836-1&amp;h=1835873835&amp;u=https%3A%2F%2Fwww.microscope.healthcare.nikon.com%2F&amp;a=Nikon+Instruments+Inc.">Nikon Instruments Inc.</a> (Nikon) to expand access to spatial biology services with the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4126836-1&amp;h=1179208902&amp;u=https%3A%2F%2Flunaphore.com%2Fproducts%2Fcomet%2F&amp;a=COMET%E2%84%A2">COMET&#x2122;</a> platform for US-based biotech, pharma, and academic customers.</p>
<p>Lunaphore's flagship COMET technology is the only fully-automated, &nbsp;high-throughput, hyperplex platform with superior tissue profiling capabilities, which performs protein detection with standard, non-conjugated antibodies. The Nikon BioImaging Lab is a research and innovation hub recently established by Nikon in the Greater Boston area, Massachusetts with the overarching mission of providing contract imaging solutions, AI-enhanced analysis and bioassay development services to foster research and drug discovery. Together,&nbsp;Lunaphore and the Nikon BioImaging Lab will be able to leverage their complementary expertise in microscopy-based imaging and analysis to bring COMET technology and spatial biology to the greater scientific community.</p>
<p>Through this partnership, in addition to access to the COMET platform, Nikon customers will also benefit from <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4126836-1&amp;h=2570928818&amp;u=https%3A%2F%2Flunaphore.com%2Fproducts%2Fhorizon%2F&amp;a=HORIZON%E2%84%A2">HORIZON&#x2122;</a>, Lunaphore's image analysis software designed for analyzing COMET hyperplex images, to further streamline image analysis workflow. Researchers and clinicians can leverage the universal end-to-end product suite to unlock the full potential of spatial biology for their research objectives.</p>
<p>"The deployment of COMET at the Nikon BioImaging Lab ensures that an expanded base of customers and researchers across the US can access the cutting-edge capabilities of our spatial biology solutions," said Matt McManus, President of Bio-Techne's Diagnostics &amp; Genomics Segment. "This strategic partnership reflects Bio-Techne and Nikon's shared commitment to bringing outstanding innovation to scientists and helping push the boundaries of research."</p>
<p>"Nikon is very excited to have a strategic partnership with Lunaphore," said Toshisada Matsuba, President, CEO at Nikon Instruments Inc.</p>
<p>"We are pleased to provide spatial biology assay services using Lunaphore's automated platform for hyperplex immunofluorescence alongside the broad range of imaging solutions we offer with our Nikon microscopes," added Fumiki&nbsp; Yanagawa, General Manager at the Nikon BioImaging Lab. "Spatial biology is a dynamic area of innovation that will shed new light on healthcare and further our understanding of human disease and health."</p>


Biotech

Bio-Techne And Nikon Instruments Inc. Announce Partnership To Expand Access To Innovative Spatial Biology Services

Bio-Techne Receives European IVDR Certification For Diagnostic Test To Monitor Chronic Myeloid Leukemia

<p>Investors eagerly anticipate the dividend payout from <b>Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)</b> on March 07, 2024. With a payout of $0.08 per share and an annualized dividend yield of 0.46%, this reward is exclusively for shareholders who held the stock before the ex-dividend date on February 09, 2024</p>
<h3>Bio-Techne Recent Dividend Payouts</h3>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><table>
<thead>
<tr>
<th><strong>Ex-Date</strong></th>
<th style="text-align: right;"><strong>Payments per year</strong></th>
<th><strong>Dividend</strong></th>
<th><strong>Yield</strong></th>
<th><strong>Announced</strong></th>
<th><strong>Record</strong></th>
<th><strong>Payable</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-09</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.46%</td>
<td>2024-02-01</td>
<td>2024-02-12</td>
<td>2024-02-26</td>
</tr>
<tr>
<td>2023-11-09</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.56%</td>
<td>2023-10-31</td>
<td>2023-11-10</td>
<td>2023-11-24</td>
</tr>
<tr>
<td>2023-08-17</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.39%</td>
<td>2023-08-08</td>
<td>2023-08-18</td>
<td>2023-09-01</td>
</tr>
<tr>
<td>2023-05-12</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.4%</td>
<td>2023-05-03</td>
<td>2023-05-15</td>
<td>2023-05-26</td>
</tr>
<tr>
<td>2023-02-10</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.39%</td>
<td>2023-02-02</td>
<td>2023-02-13</td>
<td>2023-02-27</td>
</tr>
<tr>
<td>2022-11-10</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.43%</td>
<td>2022-11-01</td>
<td>2022-11-14</td>
<td>2022-11-28</td>
</tr>
<tr>
<td>2022-08-12</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.33%</td>
<td>2022-08-04</td>
<td>2022-08-15</td>
<td>2022-08-29</td>
</tr>
<tr>
<td>2022-05-13</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.33%</td>
<td>2022-05-04</td>
<td>2022-05-16</td>
<td>2022-05-27</td>
</tr>
<tr>
<td>2022-02-10</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.34%</td>
<td>2022-02-01</td>
<td>2022-02-11</td>
<td>2022-02-25</td>
</tr>
<tr>
<td>2021-11-10</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.24%</td>
<td>2021-11-02</td>
<td>2021-11-12</td>
<td>2021-11-26</td>
</tr>
<tr>
<td>2021-08-13</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.26%</td>
<td>2021-08-05</td>
<td>2021-08-16</td>
<td>2021-08-27</td>
</tr>
<tr>
<td>2021-05-14</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.31%</td>
<td>2021-05-06</td>
<td>2021-05-17</td>
<td>2021-05-28</td>
</tr>
</tbody>
</table>
<p>Bio-Techne's dividend yield falls in the middle range when compared to its industry peers, with <b>Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>)</b> having the highest annualized dividend yield at 0.65%.</p>
<h3>Analyzing Bio-Techne Financial Health</h3>
<p>Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. </p>
<h3>YoY Growth in Dividend Per Share</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709823905_0.png" alt="dividend chart graph" /></p>
<p>From 2020 to 2023, the company experienced a reduction in its dividend per share, decreasing from $1.28 to $0.32. This decline in dividends may raise concerns among investors and warrants further analysis to understand the factors contributing to this negative trend.</p>
<h3>YoY Earnings Growth For Bio-Techne</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709823905_1.png" alt="earning chart graph" /></p>
<p>From 2020 to 2023, Bio-Techne experienced a growth in earnings per share, with an increase from $1.23 to $1.96. This positive earnings trend indicates the company's potential to enhance their cash dividend payout, which can benefit income-seeking investors.</p>
<h3>Recap</h3>
<p>This article provides an in-depth analysis of Bio-Techne's recent dividend distribution and the impact it has on shareholders. The company is currently distributing a dividend of $0.08 per share, resulting in an annualized dividend yield of 0.46%.</p>
<p>Bio-Techne's dividend yield falls in the middle range when compared to its industry peers, with Agilent Technologies having the highest annualized dividend yield at 0.65%.</p>
<p>Given that Bio-Techne has experienced a decrease in dividend per share from 2020 to 2023 along with an increase in earnings per share, it could indicate that the company is focusing on reinvesting profits into business growth rather than prioritizing dividend distributions.</p>
<p>Keeping a vigilant eye on the company's performance in the coming quarters will allow investors to stay current with any variations in financials or dividend disbursements.</p>
<p>\To read more news on Bio-Techne <a href="https://www.benzinga.com/stock//">click here</a></p>
<p><a href="https://www.benzinga.com/calendars/dividends">Click here</a> to visit our Dividends Calendar.  </p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Dividends

Bio-Techne: Commitment to Investor Contentment with Steadfast Earnings Performance

<p>By the end of today, February 26, 2024, <b>Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)</b> is set to deliver a dividend payout of $0.08 per share, equating to an annualized dividend yield of 0.46%. The company's dividend payout went ex-dividend on February 09, 2024, so only the investors that owned the stock prior to the ex-dividend date will receive this payout. </p>
<h3>Bio-Techne Recent Dividend Payouts</h3>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><table>
<thead>
<tr>
<th><strong>Ex-Date</strong></th>
<th style="text-align: right;"><strong>Payments per year</strong></th>
<th><strong>Dividend</strong></th>
<th><strong>Yield</strong></th>
<th><strong>Announced</strong></th>
<th><strong>Record</strong></th>
<th><strong>Payable</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-09</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.46%</td>
<td>2024-02-01</td>
<td>2024-02-12</td>
<td>2024-02-26</td>
</tr>
<tr>
<td>2023-11-09</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.56%</td>
<td>2023-10-31</td>
<td>2023-11-10</td>
<td>2023-11-24</td>
</tr>
<tr>
<td>2023-08-17</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.39%</td>
<td>2023-08-08</td>
<td>2023-08-18</td>
<td>2023-09-01</td>
</tr>
<tr>
<td>2023-05-12</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.4%</td>
<td>2023-05-03</td>
<td>2023-05-15</td>
<td>2023-05-26</td>
</tr>
<tr>
<td>2023-02-10</td>
<td style="text-align: right;">4</td>
<td>$0.08</td>
<td>0.39%</td>
<td>2023-02-02</td>
<td>2023-02-13</td>
<td>2023-02-27</td>
</tr>
<tr>
<td>2022-11-10</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.43%</td>
<td>2022-11-01</td>
<td>2022-11-14</td>
<td>2022-11-28</td>
</tr>
<tr>
<td>2022-08-12</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.33%</td>
<td>2022-08-04</td>
<td>2022-08-15</td>
<td>2022-08-29</td>
</tr>
<tr>
<td>2022-05-13</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.33%</td>
<td>2022-05-04</td>
<td>2022-05-16</td>
<td>2022-05-27</td>
</tr>
<tr>
<td>2022-02-10</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.34%</td>
<td>2022-02-01</td>
<td>2022-02-11</td>
<td>2022-02-25</td>
</tr>
<tr>
<td>2021-11-10</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.24%</td>
<td>2021-11-02</td>
<td>2021-11-12</td>
<td>2021-11-26</td>
</tr>
<tr>
<td>2021-08-13</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.26%</td>
<td>2021-08-05</td>
<td>2021-08-16</td>
<td>2021-08-27</td>
</tr>
<tr>
<td>2021-05-14</td>
<td style="text-align: right;">4</td>
<td>$0.32</td>
<td>0.31%</td>
<td>2021-05-06</td>
<td>2021-05-17</td>
<td>2021-05-28</td>
</tr>
</tbody>
</table>
<p>In terms of dividend yield, Bio-Techne finds itself in the middle ground among its industry peers, while <b>Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>)</b> takes the lead with the highest annualized dividend yield at 0.71%.</p>
<h3>Analyzing Bio-Techne Financial Health</h3>
<p>Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. </p>
<h3>YoY Growth in Dividend Per Share</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708959918_0.png" alt="dividend chart graph" /></p>
<p>Investors witnessed a decline in the company's dividend per share from $1.28 in 2020 to $0.32 in 2023. This downward trend in dividend payouts necessitates a comprehensive investigation to identify the reasons behind the decrease.</p>
<h3>YoY Earnings Growth For Bio-Techne</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708959918_1.png" alt="earning chart graph" /></p>
<p>From 2020 to 2023, Bio-Techne has demonstrated an upward trend in earnings, with earnings per share rising from $1.23 to $1.96. This positive earnings growth bodes well for investors looking to generate income through cash dividend payouts.</p>
<h3>Recap</h3>
<p>This article takes an in-depth look at Bio-Techne's recent dividend payout and its implications for shareholders. The company is currently distributing a dividend of $0.08 per share today, translating to an annualized dividend yield of 0.46%.</p>
<p>In terms of dividend yield, Bio-Techne finds itself in the middle ground among its industry peers, while Agilent Technologies takes the lead with the highest annualized dividend yield at 0.71%.</p>
<p>Considering the decrease in dividend per share from 2020 to 2023 along with an increase in earnings per share, Bio-Techne seems to be allocating more profits towards business expansion instead of dividend payments.</p>
<p>To remain updated on any changes in financials or dividend disbursements, investors should closely observe the company's performance in the coming quarters.</p>
<p>[Monitor live stock price updates for Bio-Techne on Benzinga.](https://www.benzinga.com/quote/<b>Bio-Techne (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tech#NASDAQ">TECH</a>)</b>)</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Bio-Techne: Bolstering Investor Value with Reduced Dividends and Amplified Earnings

<p>Stephens &amp; Co.  analyst Jacob Johnson   maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Overweight and lowers the price target from $92 to $87.</p>


Stephens & Co. Maintains Overweight on Bio-Techne, Lowers Price Target to $87

WIIM

Bio-Techne shares are trading lower after Stifel downgraded the stock from Buy to Hold and announced a $65 price target.

<p>RBC Capital has decided to maintain its Sector Perform rating of Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) and lower its price target from $85.00 to $75.00.</p>
<p>Shares of Bio-Techne are trading down 4.06% over the last 24 hours, at $65.76 per share.</p>
<p>A move to $75.00 would account for a 14.05% increase from the current share price.</p>
<h3>About Bio-Techne</h3>
<p>Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.</p>
<h3>About Analyst Ratings</h3>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know

<p>RBC Capital  analyst Conor McNamara   maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Sector Perform and lowers the price target from $85 to $75.</p>


RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $75

<p>Stifel  analyst Daniel Arias   downgrades Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Buy to Hold and announces $65 price target.</p>


Stifel Downgrades Bio-Techne to Hold, Announces $65 Price Target

Bio-Techne shares are trading lower after the company reported worse-than-expected Q2 financial results.

<p>Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.41 by 2.44 percent. This is a 14.89 percent decrease over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $272.60 million which missed the analyst consensus estimate of $277.53 million by 1.78 percent.  This is a 0.37 percent increase over sales of $271.58 million the same period last year.</p>


Earnings

Bio-Techne Q2 Adj EPS $0.40 Misses $0.41 Estimate, Sales $272.60M Miss $277.53M Estimate

AAPL

ALGM

AMZN

ATKR

BALL

BrightSphere Investment Group plc Ordinary Shares

BSIG

CLFD

COLM

COUR

CSWI

CVCO

DECK

ENSG

EVBN

EXPO

FCFS

FLWS

GOOS

HOLX

HUBG

Janus Henderson Group plc Ordinary Shares

KMPR

LANC

LESL

LPLA

MATW

MCHP

MIXT

MTSI

OCSL

ONEW

OTEX

PFSI

POST

PTON

RACE

SHEL

SILC

SIRI

SKYW

SRDX

TEAM

TSCO

VIAV

Earnings Scheduled For February 1, 2024

<p><strong>Bio-Techne</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Bio-Techne will report an <strong>earnings per share</strong> (EPS) of $0.41. </p>
<p>Bio-Techne bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.03, which was followed by a 3.29% drop in the share price the next day.</p>
<p>Here's a look at Bio-Techne's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.44</td>
<td>0.55</td>
<td>0.53</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.41</td>
<td>0.55</td>
<td>0.53</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.29%</td>
<td>-1.54%</td>
<td>-2.27%</td>
<td>-2.09%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1706709701_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Bio-Techne were trading at $72.71 as of January 29. Over the last 52-week period, shares are down 10.07%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TECH/earnings"><strong>To track all earnings releases for Bio-Techne visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Bio-Techne

<p>. The multiomics application will be commercially available in Q2 2024.<br />
&nbsp;</p>


Bio-Techne Announced That Its Spatial Biology Brands, Lunaphore And Advanced Cell Diagnostics, Will Launch The First Fully Automated Spatial Multiomics Workflow With Same-section Hyperplex Detection Of RNA And Protein Biomarkers

<p>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) today announced&nbsp;Matthew F. McManus&nbsp;has been appointed President, Diagnostics and Genomics Segment, effective&nbsp;January 8, 2024. Dr.&nbsp;McManus succeeds&nbsp;Kim Kelderman, who will become Bio-Techne&#39;s Chief Executive Officer effective&nbsp;February 1, 2024.</p>
<p>Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne&#39;s Molecular Diagnostics Division following its acquisition of Asuragen, where Dr. McManus served as President and CEO. Dr. McManus currently serves as the Chairman of the Board of Directors for ANSA, a company commercializing disruptive capabilities in gene synthesis and cell &amp; gene therapy markets. Dr. McManus received his M.D. and Ph.D. from the&nbsp;University of Pennsylvania&nbsp;School of Medicine, his MBA from&nbsp;Boston College, and his B.A. in Economics from&nbsp;College of the Holy Cross.</p>


Management

Bio-Techne President, Diagnostics and Genomics Segment, Kim Kelderman to Lead as CEO Effective February 1

Bio-Techne Announces Submission Of FDA Drug Master File For ExCellerate GMP iPSC Expansion Medium Supporting Stem Cell Therapy

Bio-Techne and Qiagen had the biggest increase in short interest levels last month - Baird

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Why do you want to consider <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>? Simply, the narrative comes down to numbers and a possible rotation.</p>



<p>First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion</a> last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion.</p>



<p>Second, a sector rotation may be underway. Yes, artificial intelligence remains a hot topic. However, after a blistering run among several AI-related enterprises, last week showed a possible slowing of momentum. However, traders might not be ready to call it a day. Rather, they&rsquo;d be looking for new opportunities.</p>



<p>What could be better than technology designed to help people? Below are biotech stocks to consider.</p>



<h2>Bio-Techne (TECH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>Based in Minneapolis, Minnesota, <strong>Bio-Techne</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tech-stock-quote/"><strong>TECH</strong></a>) develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic and bioprocessing markets. While not exactly a pure-play example among biotech stocks, Bio-Techne represents an important cog in the overall ecosystem. Since the start of the year, TECH slipped 5%.</p>



<p>Part of the problem is that the company&rsquo;s recent financial performances have been lackluster. In the third quarter of last year, Bio-Techne posted earnings per share of 41 cents, missing the 43-cent target. For Q4, it posted an EPS of 40 cents, below the 41-cent estimate. Further, for the current fiscal year, analysts see sales only reaching $1.15 billion, just 1% higher from 2023&rsquo;s result.</p>



<p>However, in 2025, they anticipate revenue of $1.25 billion. If so, that would represent almost 9% year-over-year growth. Still, if the anticipated sector rotation occurs early, there&rsquo;s no reason why TECH shouldn&rsquo;t rise sooner.</p>



<p>Covering experts rate TECH stock a <a href="https://www.tipranks.com/stocks/tech/forecast">consensus strong buy</a> with an $81.50 price target.</p>



<h2>Centessa Pharmaceuticals (CNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>Based in the U.K., <strong>Centessa Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnta-stock-quote/"><strong>CNTA</strong></a>) discovers, develops, and delivers medicines to patients. Specifically, it focuses on an activated protein C inhibitor for the <a href="https://finance.yahoo.com/quote/CNTA/profile">treatment of hemophilia A and B</a>. As well, it&rsquo;s working on an orally administered drug for the treatment of <a href="https://centessa.com/pipeline/">narcolepsy type 1 (NT1)</a>. Since the start of the year, CNTA gained almost 34%.</p>



<p>Part of the investment thesis for Centessa centers on its momentum. Over the past 52 weeks, shares gained nearly 169% of equity value. Basically, the company is attempting to recover from a disappointing public market debut back in 2021.</p>



<p>Notably, Centessa has been mitigating expected per-share losses. In Q2, the red ink came out to 26 cents per share, better than the expected 49-cent loss. And in Q3, the company disclosed a loss per share of 40 cents, better than the anticipated 52-cent loss. Management will release its Q4 results on March 28.</p>



<p>Currently, covering experts peg CNTA a <a href="https://www.tipranks.com/stocks/cnta/forecast">unanimous strong buy</a> with a $13.33 price target. Again, it could be one of the biotech stocks to consider as a momentum trade.</p>



<h2>Madrigal Pharmaceuticals (MDGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p>Based in West Conshohocken, Pennsylvania, <strong>Madrigal Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdgl-stock-quote/"><strong>MDGL</strong></a>) is a clinical-stage biopharmaceutical enterprise focused on the development of therapeutics for the <a href="https://finance.yahoo.com/quote/mdgl/profile">treatment of non-alcoholic steatohepatitis</a> (NASH) in the U.S. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p>



<p>As with a few other biotech stocks, MDGL is on the move. Since the January opener, shares gained more than 19%. Essentially, anticipation is running hot that the company could start moving into its growth phase. For the current fiscal year, analysts anticipate that sales could hit $97.04 million on average. Further, the high-side estimate calls for $155.63 million.</p>



<p>Even better, for 2025, they believe $348.93 million is a realistic consensus target for the top line. If so, we&rsquo;re talking about YOY growth of nearly 260%. Further, the high-side 2025 estimate anticipates sales of $531.6 million.</p>



<p>Covering experts rate MDGL a <a href="https://www.tipranks.com/stocks/mdgl/forecast">consensus strong buy</a> with a $369.25 average price target.</p>



<h2>Cytokinetics (CYTK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Headquartered in South San Francisco, California, <strong>Cytokinetics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cytk-stock-quote/"><strong>CYTK</strong></a>) is a late-stage biopharma focusing on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. <a href="https://www.google.com/finance/quote/CYTK:NASDAQ?hl=en">Per its public profile</a>, the company develops small-molecule drug candidates primarily engineered to impact muscle function and contractility. However, CYTK stock is risky, losing almost 23% of equity value since the start of the year.</p>



<p>Part of the reason for the red ink centers on recent poor earnings performances. For example, in Q4 of last year, the company posted a loss per share of $1.38. However, analysts were anticipating only a loss of 97 cents. It was the same story in Q3, where the loss per share was $1.35 against an expected loss of 74 cents.</p>



<p>However, the current year could be a pivot point. Per the high-side estimate, the company could generate sales of $45.43 million. And on average, analysts believe that in 2025, revenue could be $145.29 million. For context, 2023&rsquo;s top line was only $7.53 million.</p>



<p>Over the next 12 months, covering experts forecast shares <a href="https://www.tipranks.com/stocks/cytk/forecast">reaching $94.63</a>. If so, CYTK is one of the names to consider among biotech stocks.</p>



<h2>Catalyst Pharmaceuticals (CPRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/cprx-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website of Catalyst Pharmaceuticals (CPRX)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p>Founded in 2002, <strong>Catalyst Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/"><strong>CPRX</strong></a>) is a commercial-stage biopharma focusing on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. <a href="https://www.google.com/finance/quote/CPRX:NASDAQ?hl=en">Per its corporate profile</a>, Catalyst offers Firdapse, an <a href="https://catalystpharma.com/lems-clinical/">amifampridine phosphate tablet</a> for the treatment of patients with the Lambert-Eaton myasthenic syndrome (LEMS). It also offers Ruzurgi for the treatment of pediatric LEMS patients.</p>



<p>Since the start of the year, CPRX stock slipped almost 23%. However, near-term momentum suggests a possible turnaround. Some of the struggles are tied to lackluster earnings performances. From Q1 through Q3 of last year, the average <em>negative</em> earnings surprise came out to 10.23%. That&rsquo;s obviously not great. However, in Q4, the company posted EPS of 31 cents, beating the consensus target of 26 cents.</p>



<p>For the current fiscal year, analysts believe sales of $463.9 million are on tap. If so, that would handily beat last year&rsquo;s haul of $398.2 million. Further, 2025 revenue could be $561.32 million, representing 21% YOY growth.</p>



<p>CPRX enjoys a <a href="https://www.tipranks.com/stocks/cprx/forecast">unanimous strong buy</a> rating with an average price target of $25.51.</p>



<h2>Iovance Biotherapeutics (IOVA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div><p>Incorporated in 2007, <strong>Iovance Biotherapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/iova-stock-quote/"><strong>IOVA</strong></a>) develops and commercializes cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers. <a href="https://www.google.com/finance/quote/IOVA:NASDAQ?hl=en">Per its public profile</a>, Iovance offers Amtagvi, a tumor-derived autologous T-cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma.</p>



<p>IOVA happens to be one of the top movers in biotech stocks recently. Since the start of the year, shares gained nearly 72%. Over the past 52 weeks, they more than doubled in value. At first, it seems a curious development. In the first half of 2023, Iovance posted an average positive earnings surprise of nearly 37%. In the second half, the company missed the bottom-line marks.</p>



<p>However, experts believe that in 2024, Iovance will ring up $162.27 million on the top line. And in 2025, this figure could expand to $418.63 million. For context, last year&rsquo;s sales was a measly $1.19 million.</p>



<p>Perhaps best of all, IOVA enjoys a <a href="https://www.tipranks.com/stocks/iova/forecast">strong buy unanimous view</a>. The average price target stands at $26.09, making it one of the intriguing biotech stocks to consider.</p>



<h2>Silence Therapeutics (SLN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063-300x169.png" alt="Pipette adding fluid to one of several test tubes; biotech NVTA Stock"><div>Source: motorolka / Shutterstock.com</div></div><p>Incorporated in 1994 and based in the U.K., <strong>Silence Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sln-stock-quote/"><strong>SLN</strong></a>) focuses on the discovery and development of novel ribonucleic acid (<a href="https://investorplace.com/stock-quotes/rna-stock-quote/"><strong>RNA</strong></a>) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Per its <a href="https://finance.yahoo.com/quote/sln/profile">profile</a>, Silence specializes in its <a href="https://www.reuters.com/markets/companies/SLNCF.PK/">mRNAi GOLD GalNAc Oligonucleotide Discovery platform</a>, which is used to target specific disease-associated genes in the liver.</p>



<p>In addition, its specialized RNA molecules harness the body&rsquo;s natural mechanism of RNA interference, degrading mRNA molecules that encode specific targeted disease-associated proteins in a cell. Specifically, the company is developing SLN360, which is in Phase 2 trials targeting the reduction of excessive levels of lipoprotein.</p>



<p>It&rsquo;s not a profitable enterprise so it ranks among the riskier biotech stocks. However, it&rsquo;s been on a consecutive sales expansion trend since 2019. Currently, its three-year revenue growth rate stands at 47.5%.</p>



<p>Finally, covering analysts rate SLN a <a href="https://www.tipranks.com/stocks/sln/forecast">unanimous strong buy</a> with an average price target of $57.25. That implies growth of almost 151%. What&rsquo;s more, the high-side target seeks a price of $75.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/7-biotech-stocks-ready-to-ride-the-sectors-resurgence/">7 Biotech Stocks Ready to Ride the Sector&#8217;s Resurgence</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Biotech Stocks Ready to Ride the Sector's Resurgence

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Revvity: Enter Now As Reorganization Takes Shape

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Last year was a tough one for <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. The Securities and Exchange Commission reported 41 bankruptcies following the Fed&rsquo;s interest rate hiking cycle, making it difficult to finance debt.</p>



<p>Yet, by the end of the year, the biotech sector started to recover. Over one year, <strong>BlackRock&rsquo;s iShares Biotechnology ETF</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ibb-stock-quote/"><strong>IBB</strong></a></span>) is now up 10%, but down -1.3% year-to-date. Due to negative market sentiment, some biotech stocks are more discounted than others.</p>



<p>But which biotech stocks have sounder fundamentals?</p>



<h2>CRISPR Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/crispr-theraputics-crsp-stock-1600-300x169.jpg" alt="the CRISPR Therapeutics (CRSP) logo seen displayed on a smartphone"><div>Source: rafapress / Shutterstock.com</div></div><p><strong>CRISPR</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a></span>), which stands for Clustered Regularly Interspaced Short Palindromic Repeats is a gene-editing tool adapted from bacterial defense to apply as molecular scissors.</p>



<p>By cutting DNA fragments at certain points, CRISPR tech can potentially correct faulty genes and eliminate conditions stemming from them. In January, the company announced the FDA approval of gene-edited cell therapy CASGEVY for treating patients who require regular blood transfusions to stay alive.&nbsp;</p>



<p>For 2024, CRISPR Therapeutics plans to advance clinical trials across oncology, diabetes, cardiovascular and autoimmune disorders. In the <a href="https://ir.crisprtx.com/static-files/bcd12c5a-b4a4-4c63-be73-3c292c33191c">full-year 2023 filing</a>, the company reported $260.4 million in net cash used in operating activities compared to $495.7 million the year prior, attributed to Vertex payments.&nbsp;</p>



<p>While the company&rsquo;s total revenue remained relatively flat at ~$370 million, it had a $153.6 million net loss, a 76% decrease from the net loss in 2022. Overall, CRISPR Therapeutics will not need additional funding for the next two years. Twenty-eight <strong>Nasdaq</strong> analysts view CRSP&rsquo;s average price target at $86.22 vs the current $71.61 per share.</p>



<p>Owing to the wide development spectrum of gene-editing therapies, the high estimate for CRSP stock is $199, while the low forecast is $30 per share. Year-to-date, CRSP stock is up 8.4%.</p>



<h2>Moderna (MRNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/mrna1600-1-300x169.png" alt="Mobile phone with logo of American pharmaceutical company Moderna Inc. (MRNA) on screen in front of website. Focus on center-left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Moderna</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mrna-stock-quote/"><strong>MRNA</strong></a></span>) is one of the biotech stocks that was tightly wound up during the C19 vaccines rollout. Within the last year, the aptly-named MRNA stock has been down 28% but only 6.3% year-to-date, suggesting a rally from the bottom. Although tied with Pfizer for the vaccine rollout, it is yet to be shown that government-granted immunity will be torn down.</p>



<p>Much is expected of Moderna&rsquo;s cancer vaccines outside of respiratory infections, using the tweaked mRNA delivery for the immune response to fight cancer cells. In the last few decades, there has been a significantly higher <a href="https://www.nature.com/articles/s41571-022-00672-8.epdf?" target="_blank">uptick of cancer</a> in adults younger than 50.&nbsp;&nbsp;</p>



<p>Learning from the scaled-up response to C19 in 2021, Moderna will likely be a key player in this response, making it one of the biotech stocks to watch for. In the latest Q4 2023 filing, Moderna reported a net loss of $4.7 billion for the full year vs the $8.4 billion net income in 2022.</p>



<p>Yet, the company surprised investors in Q4 by reporting positive $0.55 earnings per share (<span>EPS</span>) vs expected negative $0.78. With the launch of RSV vaccines for the elderly and cancer mRNA deployment in the future, 21 analysts polled by Nasdaq place the average MRNA price target at $129.27 vs the current $105.&nbsp;</p>



<p>This is the case with all biotech stocks. The range for highs and lows is high owing to uncertain development and approvals. The high estimate for MRNA shares is $310, while the low estimate is $61 per share.</p>



<h2>Bio-Techne (TECH)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/biotecne-.png"><img width="300" height="203" src="https://investorplace.com/wp-content/uploads/2024/03/biotecne--300x203.png" alt="biotech stocks bio-techne "></a><p><strong>Bio-Techne</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tech-stock-quote/"><strong>TECH</strong></a></span>) broke even on a one-year timetable at -1.3% returns but is down -6.8% year-to-date similar to MRNA. The company is a global supplier of high-precision diagnostics, clinical products, reagents, and analytical instruments used throughout the biotech sector.</p>



<p>In other words, Bio-Techne is for the biotech stocks that <strong>Taiwan Semiconductor Manufacturing</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/tsm-stock-quote/"><strong>TSM</strong></a></span>) is for companies like <strong>Nvidia</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a></span>) and <strong>AMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amd-stock-quote/"><strong>AMD</strong></a></span>). Last Friday, the company gained EU IVDR certification for its latest leukemia diagnostics. Previously, in 2022, Forbes listed Bio-Techne on the Best Employers for Diversity list, signaling compliance with the ESG framework.</p>



<p>In the latest <a href="https://investors.bio-techne.com/press-releases/detail/405/bio-techne-releases-second-quarter-fiscal-2024-results" target="_blank">Q2 FY24 earnings</a>, Bio-Techne reported $272.6 million in net sales, with an organic revenue decline of 2% YoY. Of the last four quarters, the company beat EPS estimates only in Q2 &lsquo;23. However, with an 18% increase in operations cash flow at $142.5 million, Bio-Techne is well positioned to carry the biotech revival.</p>



<p>Based on 12 analyst insights pulled by Nasdaq, the average TECH price target is $81.5 vs the current $71.50. Because Bio-Techne is a stable biotech company, the high estimate is $95, while the low forecast is $65 per share.</p>



<p><em>On the date of publication, Shane Neagle did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Shane Neagle is fascinated by the ways in which technology is poised to disrupt investing. He specializes in fundamental analysis and growth investing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/3-biotech-stocks-that-could-be-multibaggers-in-the-making-march-edition/">3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition

Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) on April 1 and set a price target of $0.00. Pu...

Buy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic Positioning

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

In a report released on April 7, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a price targ...